Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Recombinant Poultry Virus Selectively Kills Human Prostate Cancer Cells

By BiotechDaily International staff writers
Posted on 05 Mar 2013
A recombinant form of the Newcastle disease virus (NDV) that replicates in humans only in the presence of prostate specific antigen (PSA) was found to kill prostate cancer cells, including hormone resistant cells, without damaging normal tissues.

Newcastle disease is a contagious bird disease affecting many domestic and wild avian species. The virus has a negative-sense, single-stranded genome that codes for a RNA-directed RNA polymerase, hemagglutinin-neuraminidase protein, fusion (F) protein, matrix protein, phosphoprotein, and nucleoprotein in the 5' to 3' direction. Its effects are most notable in domestic poultry due to their high susceptibility and the potential for severe impacts of an epizootic on the poultry industries. Exposure of humans to infected birds can cause mild conjunctivitis and influenza-like symptoms, but NDV otherwise poses no hazard to human health. Interest in the use of NDV as an anticancer agent has arisen from the ability of NDV to selectively kill human tumor cells with limited toxicity to normal cells. However, systemically delivered NDV fails to reach solid tumors in therapeutic concentration and also spreads poorly within the tumors due to barriers including complement, innate immunity, and extracellular matrix.

Investigators at the Virginia Polytechnic Institute (Blacksburg, USA) created a novel recombinant form of NDV in which the F protein was cleavable exclusively by human PSA.

They reported in the January 23, 2013, online edition of the Journal of Virology that the recombinant NDV replicated efficiently and specifically in prostate cancer (CaP) cells and three-dimensional prostaspheres but failed to replicate in the absence of PSA. Furthermore, PSA-cleavable recombinant NDV caused specific lysis of androgen independent and androgen responsive/nonresponsive CaP cells and prostaspheres. PSA-cleavable NDV failed to replicate in chicken embryos, indicating no pathogenicity to chickens.

"Retargeted Newcastle disease virus has major potential advantages over other cancer therapies," said senior author Dr. Subbiah Elankumaran, associate professor of virology at Virginia Polytechnic Institute. "First, its specificity for prostate cancer cells means it would not attack normal cells, thereby avoiding the various unpleasant side effects of conventional chemotherapies. In previous clinical trials, even with extremely large doses of naturally occurring strains, only mild flu-like symptoms were seen in cancer patients. Second, it would provide a new treatment for hormone-refractory patients, without the side effects of testosterone suppression that result from hormonal treatments."

Related Links:
Virginia Polytechnic Institute



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.